TORONTO and HAIFA, Israel, March 08, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV:NRX) (Germany: J90) (the “Company” or “NurExone“), a pioneering biopharmaceutical company, finalized today a lease and constructing agreement for nearly 200 square meters of laboratories and office space on the campus of the prestigious Israel Institute of Technology (“Technion“). The lease period extends until December 31, 2028, with an option to extend for an additional five years.
The Technion’s commitment to science research and biotech innovation are reflected in the decision to allocate a new facility on the university’s campus to the Company. This exclusive location will provide NurExone with ongoing access to top talent, resources and human capital from the university. The new facilities will play a pivotal role in driving the development of the Company’s revolutionary ExoPTEN and ExoTherapy platform, positioning NurExone at the forefront of exosome-based therapies advancements.
Dr. Noa Avni, Director of R&D at NurExone, states, “We’re pleased to be expanding to a cutting-edge research and development facility on the Technion campus, tailored to our present and future needs for the ExoTherapy platform and ExoPTEN development. In addition, being located at the Technion provides access to multi-million-dollar equipment and advanced facilities at the Technion, streamlining costs for the Company. We are deeply grateful to the Technion for their partnership and support.”
In the pursuit of constructing a cutting-edge facility that will cater to the needs of the …
Leave a Reply